Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366727 | 0.86 | NPC1 (0.60) | NPC1RAB9ALMNASMN1; SMN2MEN1 | |
| SCHEMBL2250256 | 0.85 | KDM4E (0.41) | NPC1RAB9ALMNASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL1504021 | 0.85 | NPC1 (0.58) | NPC1RAB9ALMNASMN1; SMN2MEN1 | |
| SCHEMBL1012343 | 0.85 | SMN1; SMN2 (0.46) | NPC1RAB9ALMNASMN1; SMN2MEN1 | |
| SCHEMBL1013645 | 0.85 | PTGS2 (0.55) | NPC1RAB9ALMNASMN1; SMN2MEN1 | |
| SCHEMBL1012450 | 0.84 | NPY5R (0.49) | NPC1RAB9ALMNASMN1; SMN2MEN1 | |
| SCHEMBL31388019 | 0.84 | TRPV1 (0.42) | NPC1RAB9ALMNASMN1; SMN2MEN1 | |
| SCHEMBL4056715 | 0.83 | NPC1 (0.45) | NPC1RAB9ALMNASMN1; SMN2MEN1 | |
| SCHEMBL1283896 | 0.83 | CDK8 (0.47) | NPC1RAB9ALMNASMN1; SMN2MEN1 | |
| SCHEMBL31265664 | 0.83 | NPC1 (0.45) | NPC1RAB9ALMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG | 2011-12-08 | — | — | US | claimed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | claimed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | claimed |
| WO-2025067411-A1 | NEK7 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119490458-A | C-3 pyrazole substituted indazole derivative and application thereof | 沈阳药科大学 | 2025-02-21 | — | — | CN | disclosed |
| WO-2025035645-A1 | C-3 PYRAZOLE SUBSTITUTED INDAZOLE DERIVATIVE AND USE THEREOF | 沈阳药科大学 | 2025-02-20 | — | — | WO | disclosed |
| CN-119060018-A | N, N-diaryl urea derivative and application thereof | 杭州百新生物医药科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| EP-1756082-A1 | 5-MORPHOLINYLMETHYLTHIOPHENYL PHARMACEUTIAL COMPOUNDS AS P38 MAP KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006059234-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006040569-A1 | THIOPHENE AMIDE COMPOUNDS FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
| EP-1615907-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astex Therapeutics Limited (GB) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005121147-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005100338-A1 | 5-MORPHOLINYLMETHYLTHIOPHENYL PHARMACEUTIAL COMPOUNDS AS P38 MAP KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-10-27 | — | — | WO | disclosed |
| WO-2004089929-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | NPC1 1372/4885RAB9A 1783/4885LMNA 2752/4885 |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | NPC1 3749/4885RAB9A 2475/4885LMNA 3225/4885 |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | NPC1 2499/4885RAB9A 1861/4885LMNA 1953/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NPC1 3749/4885RAB9A 2475/4885LMNA 3225/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NPC1 3749/4885RAB9A 2475/4885LMNA 3225/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | NPC1 3851/4885RAB9A 2456/4885LMNA 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.